Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Ascendis Pharma A/S Clear all
Recruiting No phase listed Observational

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Terminated Phase 2 Interventional

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

NCT05980598
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

NCT02781727
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
Interventions
Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
3 Years to 12 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

NCT03344458
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
1 Year to 18 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Recruiting Phase 3 Interventional

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
View directory record Official record
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

NCT05690386
View directory record Official record
Conditions
Turner Syndrome
Interventions
Lonapegsomatropin, Somatropin
Biological · Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
1 Year to 10 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

NCT04799054
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
Interventions
TransCon TLR7/8 Agonist, Pembrolizumab
Drug
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

NCT05929807
View directory record Official record
Conditions
Achondroplasia
Interventions
TransCon CNP
Drug
Lead sponsor
Ascendis Pharma Growth Disorders A/S
Industry
Eligibility
3 Years to 15 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
8
States / cities
Little Rock, Arkansas • Aurora, Colorado • Wilmington, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Recruiting No phase listed Observational

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

NCT07264634
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Palopegteriparatide
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Completed No phase listed Observational

A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia

NCT03875534
View directory record Official record
Conditions
Achondroplasia
Interventions
Not listed
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
0 Years to 8 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Little Rock, Arkansas • Oakland, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
Drug · Procedure
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

NCT03305016
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
6 Months to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

NCT04701203
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo
Combination Product
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

NCT05171855
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 81 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Torrance, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Recruiting Phase 2 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

NCT06079398
View directory record Official record
Conditions
Achondroplasia
Interventions
Navepegritide, Placebo for Navepegritide
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
0 Years to 2 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

NCT04009291
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo for TransCon PTH
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Recruiting No phase listed Observational

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT07345494
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Palopegteriparatide
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Recruiting No phase listed Observational

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

NCT05775523
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
1 Year to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia

NCT05598320
View directory record Official record
Conditions
Achondroplasia
Interventions
Navepegritide (TransCon CNP), Placebo for Navepegritide (TransCon CNP)
Drug
Lead sponsor
Ascendis Pharma Growth Disorders A/S
Industry
Eligibility
2 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Saint Paul, Minnesota • Columbia, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT07081997
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm
Combination Product
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Greeley, Colorado • Chicago, Illinois • Minneota, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

NCT04085523
View directory record Official record
Conditions
Achondroplasia
Interventions
TransCon CNP, Placebo for TransCon CNP
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Little Rock, Arkansas • Aurora, Colorado • Saint Paul, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 4, 2026, 10:17 PM EDT